Floatz logo

Lorlatinib

Diffuse Midline Glioma, H3K27-altered

Nationwide Children's HospitalSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Diffuse Midline Glioma, H3K27-altered cohort.

Asset / SponsorPhaseRating
Valproic Acid
University of Göttingen
Phase 3B
Cetuximab
University of Miami
Phase 1/2CCC
CBL-0137 FREE BASE
Children's Oncology Group
Phase 1/2CC
VIPIVOTIDE TETRAXETAN
Memorial Sloan Kettering Cancer Center
Phase 1CC
h3k27m peptide vaccine
German Cancer Research Center
Phase 1CC
Imiquimod
German Cancer Research Center
Phase 1CC
Atezolizumab
German Cancer Research Center
Phase 1CC
azd1390
Children's Oncology Group
Phase 1NR

Same molecule, other indications

Lorlatinib is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
hepatocellular carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
neoplastic meningitisDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →